Novadaq Technologies Inc.TSX: NDQ

Novadaq to present at Sachs-Bloomberg and BioContact

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, Oct. 3 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ) today
announced corporate presentations at two financial conferences. Arun Menawat,
President and Chief Executive Officer will present a corporate overview at the
Sachs-Bloomberg 5th Annual Biotech in Europe Investor Forum in Zurich,
Switzerland on Tuesday, October 4, 2005. Rick Mangat, Vice President
Operations, will also present a corporate overview at BioContact QuDebec, at
the ChFateau Frontenac, QuDebec City at 10:30 a.m. on Thursday, October 6, 2005.

About Sachs-Bloomberg 5th Annual Biotech in Europe Investor Forum
Biotech in Europe Investor Forum is a high profile life sciences event
organized in association with Bloomberg L.P. and attended by an executive
level audience of investors, pharmas, fund managers and capital raising
companies. Running over two days, the event provides roundtables on key
industry and scientific developments as well as finance and investment trends.

About BioContact Quebec 2005
BioContact QuDebec 2005 is a biopharmaceutical partnership symposium
gathering over 1200 participants. More than 150 biopharmaceutical companies,
coming from Canada, the United States, Asia and Europe, will be presenting in
different sectors of activities (diagnostics, therapeutics, and services) and
disciplines. For more information, please visit www.biocontact.qc.ca

About Novadaq Technologies
Novadaq Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY(R) Intra-operative Imaging System enables surgeons to visually assess
coronary vasculature and bypass graft functionality during the course of CABG
surgery. Novadaq's ophthalmic product, the OPTTX(TM) System, is aimed at the
diagnosis, evaluation and treatment of wet Age-related Macular Degeneration
(AMD) by using the same core imaging technology that is used in the SPY
System. The OPTTX System is currently being evaluated in clinical trials.
For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases